Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-09-07 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules. The document is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data and confirmations. The content fits the description of a 'Transaction in Own Shares' filing, which reports the company's buyback activities. Therefore, the appropriate classification is POS (Transaction in Own Shares). The document length and detail support a high confidence score.
2023-09-07 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is a Next Day Disclosure Return related to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases and cancellations of shares, confirming compliance with listing rules and legal requirements. The content focuses on share capital changes and repurchase activities, which aligns with announcements regarding share buybacks or capital changes. It is not a full financial report, earnings release, or management discussion. The document is substantive and detailed, not a brief announcement or certification. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-09-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It includes detailed information on repurchases of shares, dates, quantities, prices, and confirmations that these transactions comply with listing rules. The document is a regulatory disclosure about share repurchases and changes in capital, not a full financial report or earnings release. It fits the description of a 'Transaction in Own Shares' report, which covers company buybacks or sales of its own shares. The document length and content confirm it is not a brief announcement or a certification but a detailed disclosure of share repurchase activity.
2023-09-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Regulatory Filings Classification · 100% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2023. It details movements in issued shares, share options, warrants, convertibles, and other share-related activities for Simcere Pharmaceutical Group Limited. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for a specific month. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory filing related to share capital movements and compliance with listing rules, not a financial report or announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS).
2023-09-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules. The content focuses on share repurchase activity and capital changes rather than financial results, management changes, or regulatory certifications. The document length is over 10,000 characters and contains detailed transactional data on share repurchases. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2023-09-04 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2023
Interim / Quarterly Report Classification · 95% confidence The document is an announcement titled 'ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2023' from Simcere Pharmaceutical Group Limited. It contains detailed unaudited condensed consolidated financial results for the six months ended June 30, 2023, including revenue, profit, earnings per share, and segment performance. It also includes management discussion and analysis, business review, industry review, and detailed operational updates. The document is approximately 15,000 characters long, indicating it is a comprehensive report rather than a brief announcement or a certification. The content and period covered correspond to an interim or quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-08-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.